Basal insulin
Insulin detemir
INS_DETEMIR
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.67 (-1.19 to -0.10) | 0.32 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.64 (-1.20 to -0.07) | 0.35 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.43 (0.34 to 4.45) | 0.14 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.50 (0.04 to 5.00) | 0.19 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.30 (0.00 to 24.21) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.31 (0.00 to 23.06) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.23 (0.21 to 7.80) | 0.43 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.09 (0.15 to 7.23) | 0.49 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 1.73 (-2.43 to 6.00) | 0.14 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 2.04 (-2.72 to 6.74) | 0.16 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.98 (0.30 to 3.22) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.96 (0.29 to 3.18) | 0.52 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.55 (0.15 to 1.82) | 0.79 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.53 (0.15 to 1.77) | 0.77 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.16 (0.03 to 0.59) | 0.94 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.17 (0.03 to 0.73) | 0.89 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.94 (0.34 to 2.42) | 0.76 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.02 (0.30 to 3.29) | 0.66 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.74 (0.32 to 1.71) | 0.79 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.79 (0.32 to 1.89) | 0.72 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.41 (0.09 to 1.47) | 0.83 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.45 (0.10 to 1.65) | 0.76 |